Analyst firms · Morgan Stanley · ESPR
Morgan Stanley ESPR price target and rating history
Esperion Therapeutics Inc. (ESPR) · Health Care
Morgan Stanley rates Esperion Therapeutics Inc. (ESPR) Equal-Weight with a $9 price target, as of its latest action on Feb 3, 2023. It has published 3 rating actions on ESPR since August 2021, including 1 upgrade and 1 downgrade.
- Current rating
- Equal-Weight
- Price target
- $9
- Median target, all firms
- Too few
- Actions on ESPR
- 3
Morgan Stanley price target on ESPR
Every Morgan Stanley rating on ESPR
- Feb 3, 2023
- Oct 14, 2021
- Aug 4, 2021
How other firms rate ESPR
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| H.C. Wainwright | Neutral | May 1, 2026 | |
| Piper Sandler | Overweight | $9 | Nov 25, 2025 |
Questions about Morgan Stanley and ESPR
- What is Morgan Stanley's price target for ESPR?
- Morgan Stanley's latest stated price target for Esperion Therapeutics Inc. (ESPR) is $9, from its action on Feb 3, 2023.
- What is Morgan Stanley's rating on ESPR?
- Morgan Stanley rates ESPR Equal-Weight, a neutral rating, as of Feb 3, 2023.
- When did Morgan Stanley last change its view on ESPR?
- On Feb 3, 2023, Morgan Stanley upgrades to Equal-Weight from Underweight, price target $9.
More ESPR rating histories
All Morgan Stanley ratingsESPR news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.